HIGH-RISK ACUTE MYELOID LEUKEMIA
Clinical trials for HIGH-RISK ACUTE MYELOID LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new HIGH-RISK ACUTE MYELOID LEUKEMIA trials appear
Sign up with your email to follow new studies for HIGH-RISK ACUTE MYELOID LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug added to transplant could stop blood Cancer's return
Disease control Recruiting nowThis study is testing if adding a drug called venetoclax to the standard pre-transplant chemotherapy improves outcomes for people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). About 138 patients aged 12-60 will be randomly assigned to receive eit…
Matched conditions: HIGH-RISK ACUTE MYELOID LEUKEMIA
Phase: NA • Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Fighting Leukemia's return: new cell therapy trial offers hope after transplant
Disease control Recruiting nowThis study is testing a new cell therapy to prevent high-risk acute myeloid leukemia from coming back after a patient receives a stem cell transplant. Researchers will give patients an infusion of special immune cells called γδ T cells to see if it is safe and helps keep the canc…
Matched conditions: HIGH-RISK ACUTE MYELOID LEUKEMIA
Phase: NA • Sponsor: Donghua Zhang • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Phone app aims to ease the mental toll of leukemia treatment
Symptom relief Recruiting nowThis study is testing whether a smartphone app called DREAMLAND can help improve the quality of life and emotional well-being of adults with acute myeloid leukemia (AML) while they are in the hospital for intensive chemotherapy. The app provides coping skills, education, and psyc…
Matched conditions: HIGH-RISK ACUTE MYELOID LEUKEMIA
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Mar 23, 2026 15:18 UTC